PYCARD and cancer: Although Collard et al. [35] and Das et al. [36] reported cancer-specific hypermethylation of the PYCARD promoter in 65.5% (38/58) or 63.6% (42/66) of cases, these studies did not find any relationships between the methylation status of PYCARD and Gleason score.